T cells potentiate PTH-induced cortical bone loss through CD40L signaling

被引:96
作者
Gao, Yuhao [1 ]
Wu, Xiaojun [1 ]
Terauchi, Masakazu [1 ]
Li, Jau-Yi [1 ]
Grassi, Francesco [1 ]
Galley, Sarah [1 ]
Yang, Xiaoying [1 ]
Weitzmann, M. Neale [1 ]
Pacifici, Roberto [1 ,2 ]
机构
[1] Emory Univ, Dept Med, Div Endocrinol, Atlanta, GA 30322 USA
[2] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA
关键词
D O I
10.1016/j.cmet.2008.07.001
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Parathyroid hormone (PTH) promotes bone catabolism by targeting bone marrow (BM) stromal cells (SCs) and their osteoblastic progeny. Here we show that a continuous infusion of PTH that mimics hyperparathyroidism fails to induce osteoclast formation, bone resorption, and cortical bone loss in mice lacking T cells. T cells provide proliferative and survival cues to SCs and sensitize SCs to PTH through CD40 ligand (CD40L), a surface molecule of activated T cells that induces CD40 signaling in SCs. As a result, deletion of T cells or T cell-expressed CD40L blunts the bone catabolic activity of PTH by decreasing bone marrow SC number, the receptor activator of nuclear factor-kappa B ligand (RANKL)/OSTEOPROTE GERN (OPG) ratio, and osteoclastogenic activity. Therefore, T cells play an essential permissive role in hyperparathyroidism as they influence SC proliferation, life span, and function through CD40L. T cell-SC crosstalk pathways may thus provide pharmacological targets for PTH-induced bone disease.
引用
收藏
页码:132 / 145
页数:14
相关论文
共 55 条
[1]   CD40 ligand blocks apoptosis induced by tumor necrosis factor α, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4 [J].
Ahuja, SS ;
Zhao, SJ ;
Bellido, T ;
Plotkin, LI ;
Jimenez, F ;
Bonewald, LF .
ENDOCRINOLOGY, 2003, 144 (05) :1761-1769
[2]  
ALEXIEWICZ JM, 1990, J AM SOC NEPHROL, V1, P236
[3]   Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone [J].
Calvi, LM ;
Sims, NA ;
Hunzelman, JL ;
Knight, MC ;
Giovannetti, A ;
Saxton, JM ;
Kronenberg, HM ;
Baron, R ;
Schipani, E .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :277-286
[4]   Mechanisms of anabolic therapies for osteoporosis [J].
Canalis, Ernesto ;
Giustina, Andrea ;
Bilezikian, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :905-916
[5]   Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator [J].
Cenci, S ;
Toraldo, G ;
Weitzmann, MN ;
Roggia, C ;
Gao, YH ;
Qian, WP ;
Sierra, O ;
Pacifici, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10405-10410
[6]   Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation [J].
Chen, SH ;
Pham-Nguyen, KB ;
Martinet, O ;
Huang, YZ ;
Yang, W ;
Thung, SN ;
Chen, LP ;
Mittler, R ;
Woo, SLC .
MOLECULAR THERAPY, 2000, 2 (01) :39-46
[7]   Proximal femoral density and geometry measurements by quantitative computed tomography: Association with hip fracture [J].
Cheng, X. ;
Li, J. ;
Lu, Y. ;
Keyak, J. ;
Lang, T. .
BONE, 2007, 40 (01) :169-174
[8]   PHENOTYPE ANALYSIS OF LYMPHOCYTE SUBSETS IN NORMAL HUMAN BONE-MARROW [J].
CLARK, P ;
NORMANSELL, DE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (05) :632-636
[9]   The role of the immune system in the pathophysiology of osteoporosis [J].
Clowes, JA ;
Riggs, BL ;
Khosla, S .
IMMUNOLOGICAL REVIEWS, 2005, 208 :207-227
[10]   CD11c integrin gene promoter activity during myeloid differentiation [J].
Corbi, AL ;
LopezRodriguez, C .
LEUKEMIA & LYMPHOMA, 1997, 25 (5-6) :415-&